Hartmann Carolin, Behrendt Ann-Kathrin, Henken Stefanie, Wölbeling Florian, Maus Ulrich A, Hansen Gesine
Hannover Medical School, Department of Pediatrics and Adolescent Medicine, Pediatric Pneumology, Allergology and Neonatology, Hannover, Germany.
Hannover Medical School, Department of Experimental Pneumology, Hannover, Germany.
Immunol Lett. 2015 Mar;164(1):44-52. doi: 10.1016/j.imlet.2014.12.001. Epub 2015 Jan 6.
Colonization with Streptococcus pneumoniae (S. pneumoniae) is associated with an increased risk for recurrent wheeze and asthma. Killed S. pneumoniae showed some potential as an effective immunomodulatory therapy in a murine model of asthma. Murine studies demonstrated protection against allergic asthma by symbiotic bacteria via triggering regulatory T cell response: treatment with killed S. pneumoniae resulted in suppressed levels of allergen-specific Th2 cytokines, while early immunization generated a protective Th1 response. We investigated the impact of lung infection with live S. pneumoniae on both the development and maintenance of allergic airway inflammation and respiratory tolerance in mice. BALB/c mice were infected intratracheally with S. pneumoniae either prior to or after tolerance or allergy were induced, using ovalbumin (OVA) as model allergen. Infection of mice with S. pneumoniae prior to sensitization or after manifestation of allergic airway inflammation suppressed the development of an allergic phenotype as judged by reduced eosinophil counts in bronchoalveolar lavage fluid, decreased IgE serum levels and Th2 cytokines, relative to non-infected allergic control mice. In contrast, infection of mice with S. pneumoniae after manifestation of allergic airway inflammation combined with late mucosal re-challenge did not affect the allergic response. Moreover, induction and maintenance of respiratory tolerance to OVA challenge were not altered in S. pneumoniae-infected mice, demonstrating that mice remained tolerant to the model allergen and were protected from the development of allergic airway inflammation regardless of the time point of infection. Our results suggest that a bacterial infection may decrease the manifestation of an allergic phenotype not only prior to sensitization but also after manifestation of allergic airway inflammation in mice, whereas both, induction and maintenance of respiratory tolerance are not affected by pneumococcal pneumonia. These data may point to a role for undisturbed development and maintenance of mucosal tolerance for the prevention of allergic inflammation also in humans.
肺炎链球菌(S. pneumoniae)定植与反复喘息和哮喘风险增加相关。在哮喘小鼠模型中,灭活的肺炎链球菌显示出作为一种有效免疫调节疗法的一些潜力。小鼠研究表明,共生细菌通过触发调节性T细胞反应来预防过敏性哮喘:用灭活的肺炎链球菌治疗导致变应原特异性Th2细胞因子水平降低,而早期免疫则产生保护性Th1反应。我们研究了活的肺炎链球菌肺部感染对小鼠过敏性气道炎症的发生和维持以及呼吸耐受的影响。使用卵清蛋白(OVA)作为模型变应原,在诱导耐受或过敏之前或之后,通过气管内注射将肺炎链球菌感染BALB/c小鼠。在致敏前或过敏性气道炎症表现后用肺炎链球菌感染小鼠,相对于未感染的过敏性对照小鼠,支气管肺泡灌洗液中嗜酸性粒细胞计数减少、血清IgE水平和Th2细胞因子降低,表明过敏性表型的发展受到抑制。相比之下,在过敏性气道炎症表现后用肺炎链球菌感染小鼠并进行晚期黏膜再次激发,并不影响过敏反应。此外,肺炎链球菌感染的小鼠对OVA激发的呼吸耐受的诱导和维持没有改变,这表明无论感染时间点如何,小鼠对模型变应原仍保持耐受,并免受过敏性气道炎症的发展。我们的数据表明,细菌感染不仅可以在致敏前,而且可以在小鼠过敏性气道炎症表现后降低过敏性表型的表现,而肺炎球菌肺炎对呼吸耐受的诱导和维持均无影响。这些数据可能表明,黏膜耐受的正常发育和维持在预防人类过敏性炎症中也发挥作用。